A Phase 2 Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck, With or Without Metastases, Not Amenable to Curative Local Treatment
Latest Information Update: 06 Nov 2024
At a glance
- Drugs Cetuximab sarotalocan (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Rakuten Medical
Most Recent Events
- 07 May 2024 Status changed from active, no longer recruiting to discontinued.
- 22 Jan 2024 Planned End Date changed from 1 Apr 2024 to 1 Mar 2024.
- 24 Apr 2023 Status changed from recruiting to active, no longer recruiting.